URL copied Image Source : PTI (FILE)
Ayurveda-based Covid vaccine could soon become a reality; IIT Alumni Council secures Rs 300 crore funding
The IIT Alumni Council-founded Megalab has secured a Rs 300-crore seed funding and is developing a two-dose Ayurveda-based coronavirus vaccine that can stop the spread of the deadly virus and prevent infection within a few days of the first dose.
The city-based Megalab, set up last April by the council to drive the fight against the pandemic with ideas and money, will also be importing available vaccines from the West to be distributed first in Mumbai and then elsewhere, the alumni council president Ravi Sharma told PTI on Thursday.
Kepala Ilmuwan WHO: India Berada di Titik Kritis | DUNIA: Informasi terkini dari berbagai penjuru dunia | DW
dw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dw.com Daily Mail and Mail on Sunday newspapers.
Polisi Jerman Peringatkan Kemungkinan Pemalsuan Sertifikat Vaksinasi COVID-19 | DUNIA: Informasi terkini dari berbagai penjuru dunia | DW
dw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dw.com Daily Mail and Mail on Sunday newspapers.
New Delhi: IIT Alumni Council announces fourth generation vaccine with ayurvedic adjuvant under MegaLab initiative.
“IIT Alumni Council announces India’s first antigen-free, novel vaccine which is self-limiting, locally manufactured and based on indigenous technology. The preservative-free vaccine is being coupled with an Ayurveda inspired adjuvant which will enhance safety as well as be highly efficacious. The end objective is to deliver a continuously upgradable vaccine which can outpace the virus thus helping to end the pandemic.” said Ravi Sharma, President of the IIT Alumni Council.
“We have made remarkable progress globally in understanding vaccines since August 2020. This has helped eliminate many of the vaccine modalities being investigated and we now know that a multi-pronged approach that will elicit an antibody response which neutralises a wide variety of virus mutants is the right target to pursue. Furthermore, the potential ability to access and build upon pate
Is Covishield better or Covaxin? Everything you should know about coronavirus vaccine
Currently, people in the age group of 18-44 are getting vaccinated with two COVID-19 vaccines approved for use in India, Covaxin, and Covishield.
DNA Web Team
May 13, 2021, 04:50 PM IST
The third phase of the COVID-19 vaccination was kicked off on May 1st in India. After healthcare workers, elderly people, and 45+ people, now people in the age group of 18-44 are getting vaccinated with two COVID-19 vaccines approved for use in India, Covaxin, and Covishield.
1. Vaccination needs to be scaled up and getting vaccinated is important
1/7
Over 8 crore Indian citizens have been successfully vaccinated and lakhs of doses are being exported to other countries as well. While both Covaxin and Covishield have been deemed safe for use, and adverse reactions have been rarely observed, there are also certain possible side effects people need to be aware of. However, getting vaccinated is of utmost priority